3'-Bromomethyl-biphenyl-4-carbonitrile | 230647-29-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3'-Bromomethyl-biphenyl-4-carbonitrile
• 英文别名: 4-[3-(Bromomethyl)phenyl]benzonitrile
• CAS: 230647-29-7
• 化学式: C₁₄H₁₀BrN
• 分子量: 272.144
• InChiKey: GVAKCUQGCAZMOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-(甲氧基亚胺)-4-氧代-戊酸乙酯 、 3'-Bromomethyl-biphenyl-4-carbonitrile 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 ethyl 3-((4'-cyano-[1,1'-biphenyl]-3-yl)methyl)-2-(methoxyimino)-4-oxopentanoate
  参考文献：
  名称：

  发现吡唑羧酸作为大鼠长链l-2-羟酸氧化酶的有效抑制剂

  摘要：

  长链l -2-羟基酸氧化酶2（Hao2）是在肾脏和肝脏表达的过氧化物酶体酶。Hao2被确定为血压（BP）定量性状基因座（QTL）的候选基因，但其生理底物的身份及其在体内的作用仍然未知。为了定义该基因产物的药理作用，我们报道了Hao2选择性抑制剂的发展。我们从化合物库的筛选中确定了吡唑羧酸的命中值1和2。这些命中的线索优化导致发现15 - XV和15 - XXXII作为大鼠Hao2的有效和选择性抑制剂。该报告详述了作为Hao2特异性抑制剂的吡唑羧酸的结构活性关系。

  DOI：

  10.1016/j.bmcl.2012.05.020
• 作为产物：
  描述：

  4-(3-甲基苯基)苯甲腈 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 四氯化碳 为溶剂， 生成 3'-Bromomethyl-biphenyl-4-carbonitrile
  参考文献：
  名称：

  Benzimidazole-Based fXa inhibitors with improved thrombin and trypsin selectivity

  摘要：

  Optimization of the benzimidazole-based fXa inhibitors for selectivity versus thrombin and trypsin was achieved by substitution on the benzimidazole ring and replacement of the naphthylamidine group. Substitution of a nitro group at the 4-position on the benzimidazole improves both potency against fXa and selectivity versus thrombin. Alternatively, replacement of the naphthylamidine with either a biphenylamidine or propenylbenzamidine not only improves fXa potency and selectivity versus thrombin, but selectivity versus trypsin as well. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00145-2

文献信息

• Benzazole Potentiators of Metabotropic Glutatmate Receptors
  申请人：Govek Steven P.

  公开号：US20080176904A1

  公开（公告）日：2008-07-24

  The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.

  本发明涉及苯并咪唑化合物，其是代谢型谷氨酸受体增强剂，包括mGluR2受体，并且在与谷氨酸功能紊乱相关的神经学和精神疾病以及代谢型谷氨酸受体参与的疾病的治疗或预防中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗代谢型谷氨酸受体参与的这些疾病中的使用。
• BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Merck & Co., Inc.

  公开号：EP1855670A2

  公开（公告）日：2007-11-21
• US7960417B2
  申请人：——

  公开号：US7960417B2

  公开（公告）日：2011-06-14
• [EN] BENZAZOLE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] POTENTIALISATEURS DE BENZAZOLE DE RECEPTEURS DE GLUTAMATE METABOTROPIQUE
  申请人：MERCK & CO INC

  公开号：WO2006091496A2

  公开（公告）日：2006-08-31

  [EN] The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.
  [FR] L'invention se rapporte à des composés de benzazole qui sont des potentialisateurs de récepteurs de glutamate métabotropique, y compris le récepteur mGluR2, et qui sont utiles dans le traitement ou la prévention de troubles neurologiques et psychiatriques associés au dysfonctionnement du glutamate et aux maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués. Cette invention concerne aussi des compositions pharmaceutiques contenant ces composés, ainsi que l'utilisation de ces composés et compositions dans la prévention ou le traitement des maladies dans lesquelles les récepteurs de glutamate métabotropique sont impliqués.
• Benzimidazole-Based fXa inhibitors with improved thrombin and trypsin selectivity
  作者：Kenneth J. Shaw、William J. Guilford、Brian D. Griedel、Steve Sakata、Lan Trinh、Shung Wu、Wei Xu、Zuchun Zhao、Michael M. Morrissey

  DOI：10.1016/s0960-894x(02)00145-2

  日期：2002.5

  Optimization of the benzimidazole-based fXa inhibitors for selectivity versus thrombin and trypsin was achieved by substitution on the benzimidazole ring and replacement of the naphthylamidine group. Substitution of a nitro group at the 4-position on the benzimidazole improves both potency against fXa and selectivity versus thrombin. Alternatively, replacement of the naphthylamidine with either a biphenylamidine or propenylbenzamidine not only improves fXa potency and selectivity versus thrombin, but selectivity versus trypsin as well. (C) 2002 Elsevier Science Ltd. All rights reserved.